Robert Blaustein - 12 Aug 2025 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role: Chief Development Officer
Signature: John R. Moore, by POA from Robert Blaustein
Issuer symbol: EWTX
Transactions as of: 12 Aug 2025
Net transactions value: $0
Form type: 4
Filing time: 14 Aug 2025, 19:44:14 UTC
Previous filing: 23 Jan 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Blaustein Robert	Chief Development Officer	1715 38TH STREET, BOULDER	John R. Moore, by POA from Robert Blaustein	14 Aug 2025	0002053149

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EWTX	Restricted Stock Units	Award	$0	+17,500		$0.000000	17,500	12 Aug 2025	Common Stock	17,500	$0.000000	Direct	F1
transaction	EWTX	Stock Options (Right to buy)	Award	$0	+105,000		$0.000000	105,000	12 Aug 2025	Common Stock	105,000	$13.39	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
F2	1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.